Effect of rosiglitazone on progression of atherosclerosis: insights using 3D carotid cardiovascular magnetic resonance

Table 1 Demographic characteristics of safety population

	Rosiglitazone	Placebo	Total	P value
N (%)	(N = 27)	(N = 29)	(N = 56)
Gender
Male	21 (78%)	23 (79%)	44 (79%)	P = 0.85
Female	6 (22%)	6 (21%)	12 (21%)	P = 0.85
Age (years)
Mean ± SD	62.2 ± 8.2	65.6 ± 6.1	63.9 ± 7.4	P = 0.072
Median	65.0	66.0	65.0
Range	38 – 74	55 – 75	38 – 75
Race
White	17 (63%)	18 (62%)	35 (63%)	P = 0.84
Black	3 (11%)	4 (14%)	7 (13%)	P = 1.00
Oriental	1 (4%)	0	1 (2%)	P = 0.48
Other	6 (22%) Asian-4, Bangladeshi-1, Brazilian-1	7 (24%) Asian-4, Bangladeshi-1, Indian-1, Yemeni-1	13 (23%)	P = 0.88
Statin/fibrate use
Yes	21 (78%)	24 (83%)	45 (80%)	P = 0.90
No	6 (22%)	5 (17%)	11 (20%)	P = 0.89
Smoking history
Never	6 (22%)	12 (41%)	18 (32%)	P = 0.21
Former	16 (59%)	13 (45%)	29 (52%)	P = 0.42
Current	5 (19%)	4 (14%)	9 (16%)	P = 0.73
Number of years smoked¹
Mean ± SD	33.5 ± 12.7	34.3 ± 14.8	33.9 ± 13.5	P = 0.83
Median	32.0	39.0	34.0
Range	7 – 63	7 – 56	7 – 63
Number of cigarettes per day¹
Mean ± SD	22.9 ± 21.5	21.7 ± 13.8	22.3 ± 18.2	P = 0.80
Median	20.0	20.0	20.0
Range	3 – 100	3 – 60	3 – 100
Weight (kg)
Mean ± SD	78.1 ± 13.8	81.8 ± 14.1	80.0 ± 13.9	P = 0.59
Median	77.4	80.5	79.0
Range	60.5 – 117.4	56.0 – 116.2	56.0 – 117.4
Height (cm)
Mean ± SD	167.3 ± 8.8	169.0 ± 6.2	168.2 ± 7.6	P = 0.40
Median	170.0	169.0	169.0
Range	151 – 187	157 – 179	151 – 187
BMI (kg/m²)
Mean ± SD	27.9 ± 4.1	28.6 ± 4.3	28.3 ± 4.2	P = 0.77
Median	27.9	28.5	28.0
Range	22.4 – 39.2	20.6 – 37.1	20.6 – 39.2

1. Data only for current and former smokers (rosiglitazone group-21; placebo group-17).

ISSN: 1532-429X